Exscientia
Latest
AI-formulated medicine to be tested on humans for the first time
A drug designed entirely by artificial intelligence is about to enter clinical human trials for the first time. The drug, which is intended to treat obsessive-compulsive disorder, was discovered using AI systems from Oxford-based biotech company Exscientia. While it would usually take around four and a half years to get a drug to this stage of development, Exscientia says that by using the AI tools it's taken less than 12 months.
GSK will use supercomputers to develop new drugs
Developing a new drug is a long, complicated and expensive process that takes years before you get to the human trial. There's a hope that computers will be able to simulate the majority of the process, greatly reducing the cost and time involved. That's why GlaxoSmithKline is throwing $43 million in the direction of Scottish AI company Exscientia, which promises to use deep learning to find new drugs.
